Joel Topf
@kidneyboy.bsky.social
Saying the product of the kidneys is urine is like saying the product of a factory is pollution. Urine is a by-product. The product is homeostasis.
COI: https://pbfluids.com/about/
COI: https://pbfluids.com/about/
Reposted by Joel Topf
As one of the original flozinators it so maddening to see nephrologists flozinate *instead* of using immunosuppresants, dz modifying therapies in nonDM CKD. Consider a thought experiment in transplant: proteinuria is often how we pick up ABMR & an SGLT2i is the wrong answer. Now do IgAN, SLE,C3G etc
November 10, 2025 at 2:18 PM
As one of the original flozinators it so maddening to see nephrologists flozinate *instead* of using immunosuppresants, dz modifying therapies in nonDM CKD. Consider a thought experiment in transplant: proteinuria is often how we pick up ABMR & an SGLT2i is the wrong answer. Now do IgAN, SLE,C3G etc
Reposted by Joel Topf
November 8, 2025 at 5:40 PM
November 8, 2025 at 5:21 PM
Reposted by Joel Topf
Richard Haynes- professor at Oxford, nephrologist. Senior author EMPA-k , 3C etc etc…..
November 8, 2025 at 5:05 PM
Richard Haynes- professor at Oxford, nephrologist. Senior author EMPA-k , 3C etc etc…..
Reposted by Joel Topf
Was listening to nephjc freely filtered episode of ACHIEVE trial just the other day. Of all the things we've tried in HD and failed, and now fish oil does the trick??? @kidneyboy.bsky.social @hswapnil.medsky.social
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
November 7, 2025 at 11:40 PM
Was listening to nephjc freely filtered episode of ACHIEVE trial just the other day. Of all the things we've tried in HD and failed, and now fish oil does the trick??? @kidneyboy.bsky.social @hswapnil.medsky.social
If you are coming to the NephJC party tonight catch the bus at 7:00 at the corner Avenida De Las Americas & Rusk St at the corner of the conference center nearest Hall A. Near the restaurant, Grotto.
November 7, 2025 at 11:19 PM
If you are coming to the NephJC party tonight catch the bus at 7:00 at the corner Avenida De Las Americas & Rusk St at the corner of the conference center nearest Hall A. Near the restaurant, Grotto.
Reposted by Joel Topf
Recall only a few years ago that the late breaking trials session often has post hoc observation analyses or another negative HD or AKI trial. Indeed it is fantastic. More tomorrow…
November 7, 2025 at 7:52 AM
Recall only a few years ago that the late breaking trials session often has post hoc observation analyses or another negative HD or AKI trial. Indeed it is fantastic. More tomorrow…
Reposted by Joel Topf
I might have a new career in industry, but another #KidneyWk calls for another Kidney Week Run Club! From now on it will be organized by @nephjc.bsky.social (basically @kidneyboy.bsky.social). Saturday morning, 6:30 am, Discovery Green. 3 miles + change.
November 7, 2025 at 2:33 AM
I might have a new career in industry, but another #KidneyWk calls for another Kidney Week Run Club! From now on it will be organized by @nephjc.bsky.social (basically @kidneyboy.bsky.social). Saturday morning, 6:30 am, Discovery Green. 3 miles + change.
Reposted by Joel Topf
Dr Vlado Perkovic kicks off plenary session. Missed it? Check out the simultaneous publication. #KidneyWk www.kidney-international.org/article/S008...
From Progression to Remission: A New Paradigm for Success in Chronic Kidney Disease
Recent advances in treatment of chronic kidney disease (CKD) have changed the clinical
paradigm from slowing inevitable progression to achievable remission. Landmark trials
involving SGLT2 inhibitors,...
www.kidney-international.org
November 6, 2025 at 2:35 PM
Dr Vlado Perkovic kicks off plenary session. Missed it? Check out the simultaneous publication. #KidneyWk www.kidney-international.org/article/S008...
Reposted by Joel Topf
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 6, 2025 at 2:55 PM
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Reposted by Joel Topf
#NephJC at #KidneyWk
🔥🔥We have all sorts of events
🗓️ Friday, a classic: #NephJC night- #NephJCKidney Awards,
@freelyfiltered.bsky.social
live recording + lots of fun
🗓️ Saturday, Nov 8th, 6:30 am- will start the day with a nephro run 🏃🏃
For more info 👇👇
www.nephjc.com
🔥🔥We have all sorts of events
🗓️ Friday, a classic: #NephJC night- #NephJCKidney Awards,
@freelyfiltered.bsky.social
live recording + lots of fun
🗓️ Saturday, Nov 8th, 6:30 am- will start the day with a nephro run 🏃🏃
For more info 👇👇
www.nephjc.com
NephJC
www.nephjc.com
November 5, 2025 at 8:15 PM
#NephJC at #KidneyWk
🔥🔥We have all sorts of events
🗓️ Friday, a classic: #NephJC night- #NephJCKidney Awards,
@freelyfiltered.bsky.social
live recording + lots of fun
🗓️ Saturday, Nov 8th, 6:30 am- will start the day with a nephro run 🏃🏃
For more info 👇👇
www.nephjc.com
🔥🔥We have all sorts of events
🗓️ Friday, a classic: #NephJC night- #NephJCKidney Awards,
@freelyfiltered.bsky.social
live recording + lots of fun
🗓️ Saturday, Nov 8th, 6:30 am- will start the day with a nephro run 🏃🏃
For more info 👇👇
www.nephjc.com
Reposted by Joel Topf
Vlado is so interesting. I loved getting a chance to follow up on his state of the art lecture
Joel Topf @kidneyboy.bsky.social spoke with Vlado Perkovic following his #KidneyWk lecture on how we can cure kidney disease. Stay tuned to nephtimes.com for the video.
November 6, 2025 at 8:03 PM
Vlado is so interesting. I loved getting a chance to follow up on his state of the art lecture
November 6, 2025 at 6:17 PM
November 6, 2025 at 3:34 PM
November 6, 2025 at 3:31 PM
Reposted by Joel Topf
The answer is primary care access and cheap meds.
November 6, 2025 at 2:52 PM
The answer is primary care access and cheap meds.
November 6, 2025 at 2:56 PM